Current and historical daily PE Ratio for Mesoblast Ltd (
) from 2006 to Apr 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Mesoblast stock (MEOBF) PE ratio as of Apr 19 2024 is 0.09.
More Details
Mesoblast Ltd (MEOBF) PE Ratio (TTM) Chart
Mesoblast Ltd (MEOBF) PE Ratio (TTM) Historical Data
View and export this data going back to 2006. Start your Free Trial
Total 1210
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Mesoblast PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-19 | 0.1 | 2024-02-14 | 0.0 |
| 2024-04-18 | 0.1 | 2024-02-13 | 0.0 |
| 2024-04-17 | 0.1 | 2024-02-12 | 0.0 |
| 2024-04-16 | 0.1 | 2024-02-09 | 0.0 |
| 2024-04-15 | 0.1 | 2024-02-08 | 0.0 |
| 2024-04-12 | 0.1 | 2024-02-07 | 0.0 |
| 2024-04-11 | 0.1 | 2024-02-06 | 0.0 |
| 2024-04-10 | 0.1 | 2024-02-05 | 0.0 |
| 2024-04-09 | 0.1 | 2024-02-02 | 0.0 |
| 2024-04-08 | 0.1 | 2024-02-01 | 0.0 |
| 2024-04-05 | 0.1 | 2024-01-31 | 0.0 |
| 2024-04-04 | 0.1 | 2024-01-30 | 0.0 |
| 2024-04-03 | 0.1 | 2024-01-29 | 0.0 |
| 2024-04-02 | 0.1 | 2024-01-26 | 0.0 |
| 2024-04-01 | 0.1 | 2024-01-25 | 0.0 |
| 2024-03-28 | 0.1 | 2024-01-24 | 0.0 |
| 2024-03-27 | 0.0 | 2024-01-23 | 0.0 |
| 2024-03-26 | 0.0 | 2024-01-22 | 0.0 |
| 2024-03-25 | 0.0 | 2024-01-19 | 0.0 |
| 2024-03-22 | 0.0 | 2024-01-18 | 0.0 |
| 2024-03-21 | 0.0 | 2024-01-17 | 0.0 |
| 2024-03-20 | 0.0 | 2024-01-16 | 0.0 |
| 2024-03-19 | 0.0 | 2024-01-12 | 0.0 |
| 2024-03-18 | 0.0 | 2024-01-11 | 0.0 |
| 2024-03-15 | 0.0 | 2024-01-10 | 0.0 |
| 2024-03-14 | 0.0 | 2024-01-09 | 0.0 |
| 2024-03-13 | 0.0 | 2024-01-08 | 0.0 |
| 2024-03-12 | 0.0 | 2024-01-05 | 0.0 |
| 2024-03-11 | 0.0 | 2024-01-04 | 0.0 |
| 2024-03-08 | 0.0 | 2024-01-03 | 0.0 |
| 2024-03-07 | 0.0 | 2024-01-02 | 0.0 |
| 2024-03-06 | 0.0 | 2023-12-29 | 0.0 |
| 2024-03-05 | 0.0 | 2023-12-28 | 0.0 |
| 2024-03-04 | 0.0 | 2023-12-27 | 0.0 |
| 2024-03-01 | 0.0 | 2023-12-26 | 0.0 |
| 2024-02-29 | 0.0 | 2023-12-22 | 0.0 |
| 2024-02-28 | 0.0 | 2023-12-21 | 0.0 |
| 2024-02-27 | 0.0 | 2023-12-20 | 0.0 |
| 2024-02-26 | 0.0 | 2023-12-19 | 0.0 |
| 2024-02-23 | 0.0 | 2023-12-18 | 0.0 |
| 2024-02-22 | 0.0 | 2023-12-15 | 0.0 |
| 2024-02-21 | 0.0 | 2023-12-14 | 0.0 |
| 2024-02-20 | 0.0 | 2023-12-13 | 0.0 |
| 2024-02-16 | 0.0 | 2023-12-12 | 0.0 |
| 2024-02-15 | 0.0 | 2023-12-11 | 0.0 |
Mesoblast Ltd (MEOBF) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Mesoblast Ltd
NAICS : 541711
ISIN : AU000000MSB8
Share Class Description:
MEOBF: Ordinary SharesCompare
Compare
Traded in other countries / regions
MSB.AustraliaMESO.USALWB.Germany IPO Date
2006-10-31Description
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers